Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1]
P.J. Dyck, K.M. Kratz, J.L. Karnes.
The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study.
Neurology, 43 (1993), pp. 2345-2352
[2]
K.F. Amthor, K. Dahl-Jorgensen, T.J. Berg.
The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study.
Diabetologia, 37 (1994), pp. 579-584
[3]
P. Reichard, B. Berglund, A. Britz.
Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years.
J Intern Med, 230 (1991), pp. 101-110
[4]
H. Lesser, U. Sharma, L. LaMoreaux, R.M. Poole.
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
Neurology, 63 (2004), pp. 2104
[5]
J.C. Fehrenbacher, C.P. Taylor, M.R. Vasko.
Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C.
Pain, 105 (2003), pp. 133-138
[6]
R. Freynhagen, K. Strojek, T. Griesing, E. Whalen, M. Balkenohl.
Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens.
Pain, 115 (2005), pp. 254-260
[7]
Pfizer Lyrica will undergo phase IV vision, nerve impairment studies. The Pink Sheet. 2005;67:7-19.
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición